<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92404">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01900054</url>
  </required_header>
  <id_info>
    <org_study_id>TAU-284-18</org_study_id>
    <nct_id>NCT01900054</nct_id>
  </id_info>
  <brief_title>A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long-term safety and efficacy of TAU-284
      (Bepotastine besilate) in pediatric patients with perennial allergic rhinitis for 12 weeks
      administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter,open-label, single-arm, uncontrolled study to evaluate the safety and
      efficacy of TAU-284 (20 mg/day) in pediatric patients with perennial allergic rhinitis for
      12 weeks administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse events and adverse drug reactions</measure>
    <time_frame>Up to Week 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total score for the three major nasal symptoms [sneezing, rhinorrhea, and nasal congestion]</measure>
    <time_frame>baseline, Week2, Week4, Week6, Week8, Week10, Week 12 and final evaluation point</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in individual nasal symptom scores (sneezing, rhinorrhea, nasal congestion, and impairment in daily activities)</measure>
    <time_frame>baseline, Week2, Week4, Week6, Week8, Week10 and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in individual scores for local nasal findings (rhinoscopic findings)</measure>
    <time_frame>Second enrollment, Week2, Week4, Week6, Week8, Week10 and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in severity score for symptoms of allergic rhinitis</measure>
    <time_frame>baseline, Week2, Week4, Week6, Week8, Week10 and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of activities in daily life(study, outing, sleeping)</measure>
    <time_frame>Second enrollment, Week2, Week4, Week6, Week8, Week10 and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient impression of nasal symptoms(sneezing, rhinorrhea, nasal congestion, nasal pruritus, eye pruritus and eye tearing)</measure>
    <time_frame>Week 12 or suspension</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>TAU-284</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bepotastine besilate</intervention_name>
    <description>Two TAU-284 5mg tablets will be taken orally twice a day</description>
    <arm_group_label>TAU-284</arm_group_label>
    <other_name>TALION 5mg tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 7 and 15 years

          -  Patients who have received a diagnosis of perennial allergic rhinitis according to
             the diagnostic criteria

          -  Patients with a mean total score for the three major nasal symptoms [sneezing,
             rhinorrhea, and nasal congestion] of at least 3 on the basis of symptoms recorded in
             the nasal allergy diary during the observation period  etc.

        Exclusion Criteria:

          -  Patients with vasomotor rhinitis or eosinophilic rhinitis

          -  Patients who have concurrent nasal disease that may affect the efficacy of TAU-284

          -  Patients with a history of any of the nasal surgical procedures

          -  Patients with current or previous history of drug allergy

          -  Patients who concurrently have renal function abnormalities that may cause safety
             problems  etc.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KIMIHIRO OKUBO</last_name>
    <role>Study Director</role>
    <affiliation>Nippon Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reserch site</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>July 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAU-284</keyword>
  <keyword>Bepotastine besilate</keyword>
  <keyword>Histamine H1 receptor antagonists</keyword>
  <keyword>children</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Histamine H1 Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
